.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Federal Trade Commission
Express Scripts
Citi
Cipla
Moodys
Boehringer Ingelheim
Queensland Health
McKesson
Argus Health

Generated: December 14, 2017

DrugPatentWatch Database Preview

STALEVO 150 Drug Profile

« Back to Dashboard

When do Stalevo 150 patents expire, and when can generic versions of Stalevo 150 launch?

Stalevo 150 is a drug marketed by Orion Pharma and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-six patent family members in forty countries.

The generic ingredient in STALEVO 150 is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Orion PharmaSTALEVO 150carbidopa; entacapone; levodopaTABLET;ORAL021485-003Jun 11, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Orion PharmaSTALEVO 150carbidopa; entacapone; levodopaTABLET;ORAL021485-003Jun 11, 2003ABRXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: STALEVO 150

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Orion PharmaSTALEVO 150carbidopa; entacapone; levodopaTABLET;ORAL021485-003Jun 11, 2003► Subscribe► Subscribe
Orion PharmaSTALEVO 150carbidopa; entacapone; levodopaTABLET;ORAL021485-003Jun 11, 2003► Subscribe► Subscribe
Orion PharmaSTALEVO 150carbidopa; entacapone; levodopaTABLET;ORAL021485-003Jun 11, 2003► Subscribe► Subscribe
Orion PharmaSTALEVO 150carbidopa; entacapone; levodopaTABLET;ORAL021485-003Jun 11, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for STALEVO 150

Drugname Dosage Strength RLD Submissiondate
carbidopa, levodopa and entacaponeTablets25/100/200 mg and 37.5/150/200 mgStalevo 1506/29/2007

International Patent Family for Tradename: STALEVO 150

Country Document Number Estimated Expiration
Japan4204783► Subscribe
Japan2003503454► Subscribe
Estonia05473► Subscribe
Bulgaria106251► Subscribe
Malaysia127685► Subscribe
Estonia200100716► Subscribe
Colombia5180579► Subscribe
Yugoslavia92501► Subscribe
Portugal1189608► Subscribe
Finland991485► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Harvard Business School
Fish and Richardson
Johnson and Johnson
Boehringer Ingelheim
Farmers Insurance
Argus Health
Merck
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot